Collaborative Initiatives

April 14, 2016

Internationalization

- Collaborations with EORTC*/IMIQuIC-ConCePT**
- European Society of Radiology (ESR): European Imaging Biomarkers Alliance (EIBALL), a subcommittee of the ESR Research Committee
- Japan Radiological Society: QIBA-Japan
- Other efforts: Korean Radiological Society, São Paulo Neuro Clinical Trial

*European Organisation for Research and Treatment of Cancer
**Innovative Medicines Initiative Quantitative Imaging in Cancer: Connecting Cellular Processes with Therapy
Internationalization – EIBALL

- Report submitted by Siegfried Trattnig, EIBALL Chair.

- The chair of EIBALL is a member of the QIBA Steering Committee. The QIBA Chair is a member of EIBALL.

- Most recent meeting held on March 3, 2016 during ECR Meeting in Vienna, Austria.

Internationalization – EIBALL

- Update on Collaboration with EORTC*
  - Approval by EORTC leadership to have two imaging liaisons representatives always included on each strategy committee of the EORTC disease oriented groups (DOGs) as ex officio members to influence upstream new clinical trials and include advanced imaging. Thus, the imaging component could be discussed at an early stage to ensure adequate support when imaging is used as a primary endpoint.
  - Three EIBALL SC members are active members of the EORTC Imaging Group (one as vice-chair, one as a secretary and one as the former president). The next meeting of the EORTC Imaging Group takes place April 11, 2016.
  - Collaboration on EORTC-1423-IG-GITCG: Evaluation of diffusion-weighted MRI in patients with resectable liver metastases from colorectal cancer treated with preoperative therapy. EIBALL and QIBA were both involved in this study using DWI as a primary endpoint, and it is anticipated a manuscript will be submitted describing the DWI phantom used for this multicenter trial.

*European Organisation for Research and Treatment of Cancer
Internationalization – EIBALL

• EIBALL is collaborating with EORTC and ESOI* on the training of future cancer imagers with regard to quantitative imaging with the joint educational courses on tumor staging and tumor therapy response assessment with hands-on courses and training in the implementation of imaging in clinical trials.

*European Society of Oncologic Imaging

Internationalization – EIBALL

• Collaboration with the European Institute for Biomedical Imaging Research (EBIR)
  • Official application for joint initiative of EIBR and EIBALL was approved at the March 2016 EIBIR General Meeting.
  • One of the first tasks: Update on the list of “core institutions” in Europe in which imaging biomarker development and studies are feasible and performed, and development of a network of collaborating institutions. An imaging facility database for potential sites in multicentre clinical trials will make the initiation phase of trials by EORTC more efficient.
  • EIBIR would be the “operational arm”, while EIBALL would be the “strategic arm” as EIBALL is not a legal entity and can only play an advisory role.
  • For now, EIBALL remains a subcommittee of the ESR Research Committee.
Internationalization – EIBALL

• Potential future EIBALL activity: Accreditation of centers for certain quality criteria (similar to EANM) => potential collaboration with QIBA.

• Potential EIBALL – QIBA collaboration on standardization of MR ASL (arterial spin labeling)
  • Xavier Golay/Gold Standard Phantoms proposal.
  • Due to limited resources of QIBA, EIBALL suggests the formation of a “European Task Force on ASL” within the QIBA PDF-MRI Biomarker Committee.

• Other EIBALL contributions to projects, including IMI-TRISTAN Project applications, EU Cost Project, MR Fingerprinting, etc.

Internationalization – JRS

• Report submitted by Tomio Inoue, JRS.
Internationalization – JRS

QI Educational Activities
1. Osaka workshop on February 14, 2015
2. Yokohama workshop on February 27, 2015
3. Yokohama workshop on August 20, 2015
4. International meeting on Drug Development and Molecular Imaging, organized by JSNM and Dept. of Radiology in YCU on September 28, 2015 (Yokohama)
5. JRS Autumn Assembly in Morioka on October 3, 2015

Internationalization – JRS

The 75th Annual Meeting of the Japan Radiological Society, April 14-17, 2016 (Yokohama)

• Special Project on QIBA (Quantitative Imaging Biomarkers Alliance)
  • Keynote
    • “From Qualitative to Quantitative: The Role of the RSNA Quantitative Imaging Biomarkers Alliance (QIBA)”
    • Edward Jackson
  • Additional Presentation
    • “What does RSNA/QIBA expect of the Japan/QIBA activity?”
    • Kevin O’Donnell
  • Presentations describing the proposed direction of QIBA-Japan and reports on current RSNA/QIBA activities from each modality committee in Japan.
  • A representative from JIRA (Japan Medical Imaging and Radiological Systems Industries Association) will be present and invited to comment.
Internationalization – JRS

Some Specific Direction for Future Activities

- MR – There is significant interest in QIBA-Japan MRE efforts. It was proposed that a Japanese Society for Magnetic Resonance in Medicine (JSMR) – QIBA joint committee meet twice per year.
- NM – There is interest in learning more of the QIBA process and to implement key aspects in Japan, in cooperation with the Japanese Society of Nuclear Medicine (JSNM). There is a specific interest in developing guidelines for standardization of analysis software.
- CT – Similar to NM, there is a specific interest in developing guidelines for standardization of software.
- Meeting with Dr. Jackson and Mr. O’Donnell on Sunday, April 17, 2016.

National Biomarker Development Alliance

NBDA Convergence Conference III: Imaging

- “Toward Standards for Imaging Site Qualifications in Clinical Trials with Imaging Endpoints”
- July 27-28, 2015
ACR

• Collaboration between QIBA and ACR
• Access to a set of CT Accreditation Program (CTAP) phantom data (deidentified)
• Project leader: Ehsan Samei, PhD – Duke
• Data analyses based on prior QIBA-funded projects
• Results to be shared with ACR CT Physics Subcommittee of the CTAP (a “win-win” situation)
NIBIB

• Presentation to NIBIB Leadership
• June 1, 2016
• FDA, Industry, and Clinical Practice Perspectives on Importance of QIBA Activities